Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Excess tax benefits associated with employee equity plans

Excess tax benefits associated with employee equity plans at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$4.56M+6.7%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's excess tax benefits associated with employee equity plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's excess tax benefits associated with employee equity plans?
ADMA Biologics (ADMA) reported excess tax benefits associated with employee equity plans of -$2M in Q4 2025.
How has ADMA Biologics's excess tax benefits associated with employee equity plans changed year-over-year?
ADMA Biologics's excess tax benefits associated with employee equity plans decreased by 41.3% year-over-year, from -$1.42M to -$2M.
What does excess tax benefits associated with employee equity plans mean?
The dollar value of tax benefits realized from share-based compensation arrangements that exceed the tax expense recognized in the financial statements. This reflects the favorable tax impact of stock option exercises or restricted stock vesting on the company's bottom line.